VJHemOnc is committed to improving our service to you

iwCLL 2019 | iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil

VJHemOnc is committed to improving our service to you

Alessandra Tedeschi

Alessandra Tedeschi, MD, Niguarda Cancer Center, Milan, Italy, discusses the 4-year update of the iLLUMINATE study (NCT02264574) looking at ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab as first-line treatment in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter